Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in generalized myasthenia gravis
NCT04818671Phase 3Completed
- Sponsor
- argenx
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Antibody Fragments
- Countries
- 12
01
Overview
A Phase 3 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Started Apr 2021; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04818671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04818671.